ABOUT EVENT
What did the Biophysics for Drug Discovery Summit Explore?
With increasing therapeutic successes for easy to reach targets, what remains to be overcome are complex targets posing an intricate web of challenges to biophysicists looking to create a new era of transformative therapies.
Despite technological advancements, the need for biophysicists focusing on early-stage drug discovery to come together, share innovative ideas, and harness transferrable lessons from across targets and modalities to inform efficient drug discovery has never been more apparent.
In April 2024, the Inaugural Biophysics for Drug Discovery Summit navigated beyond low-hanging fruit with pharma and biotech leaders in pre-competitive troubleshooting, exploring cutting-edge biophysical technologies and approaches to advance hit to lead.
This summit helped attendees gain insights into harnessing multiple techniques, tackling challenging targets, and improving screening efficiency through exclusive case study sessions.
80+
GLOBAL ATTENDEES
5+
HOURS OF NETWORKING
22+
EXPERT SPEAKERS
3
DEEP DIVE WORKSHOPS
What Did Attendees Learn?
 |
Maximise biophysical techniques pushing biophysics to the limits to unlock maximum insight and optimize and streamline drug discovery with Merck, UCB and Boehringer Ingelheim. |
|
Innovative approaches in Hit Identification and Hit Validation to uncover practical insights into risk mitigation strategies, balancing the potential of hits with uncertainties in target engagement and selectivity with Merck and Foghorn Therapeutics. |
|
Explore the nuanced decision-making strategies guiding scientists through the intricate web of choices in the crucial transition from hits to leads to better shape the trajectory of your drug discovery and development with Pfizer, Roche and Kestrel Therapeutics. |
|
Uncover how industry peers are utilizing biophysical techniques to solve novel problems for complex systems and hard to reach targets to propel the industry forward with Odyssey Therapeutics, Expansion Therapeutics and Biogen. |
- Maximise biophysical techniques pushing biophysics to the limits to unlock maximum insight and optimize and streamline drug discovery with Merck, UCB and Boehringer Ingelheim.
- Delve into the innovative approaches in Hit Identification and Hit Validation to uncover practical insights into risk mitigation strategies, balancing the potential of hits with uncertainties in target engagement and selectivity with Merck and Foghorn Therapeutics.
- Explore the nuanced decision-making strategies guiding scientists through the intricate web of choices in the crucial transition from hits to leads to better shape the trajectory of your drug discovery and development with Pfizer, Roche and Kestrel Therapeutics.
- Uncover how industry peers are utilizing biophysical techniques to solve novel problems for complex systems and hard to reach targets to propel the industry forward with Odyssey Therapeutics, Expansion Therapeutics and Biogen.
What Did Your Peers Say
“All things in the universe are governed by a certain set of laws. Understanding those laws and applying them to drug discovery excites me. I look forward to learning more about the inclusion of biophysics in the drug development process.”
Kyle Martin, Senior Scientist, Boehringer Ingelheim
“The drug target space that is accessible with biophysical approaches is constantly growing due to innovation in protein science and refinement of biophysical techniques. The Biophysics in Drug Discovery Summit brings together experts from across the industry to exchange on recent advancements in the field.”
Arne Rufer, Expert Scientist, Lead Discovery, Roche
“This conference has a fantastic line-up of speakers and will help clarify the suitability of different biophysical techniques tailored to different target types and different questions in the process of small molecule drug invention.”
Laura Silvian, Senior Director, Biogen